VERU 📈 Veru - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92536C1036

VERU: Condoms, Cancer treatments, ARDS treatments

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Web URL: https://verupharma.com

Additional Sources for VERU Stock

VERU Stock Overview

Market Cap in USD 105m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Personal Care Products
IPO / Inception 1990-07-19

VERU Stock Ratings

Growth 5y -64.5%
Fundamental -64.4%
Dividend 7.43%
Rel. Strength Industry -192
Analysts 4.2/5
Fair Price Momentum 0.52 USD
Fair Price DCF -

VERU Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y 0.00%
Payout Consistency 24.8%

VERU Growth Ratios

Growth Correlation 3m -69.5%
Growth Correlation 12m 22.5%
Growth Correlation 5y -57.6%
CAGR 5y -26.27%
CAGR/Mean DD 5y -0.41
Sharpe Ratio 12m 0.34
Alpha -22.08
Beta 0.42
Volatility 101.99%
Current Volume 1503.1k
Average Volume 20d 1123k
What is the price of VERU stocks?
As of December 22, 2024, the stock is trading at USD 0.65 with a total of 1,503,100 shares traded.
Over the past week, the price has changed by -15.55%, over one month by +0.29%, over three months by -21.49% and over the past year by -12.47%.
Is Veru a good stock to buy?
No, based on ValueRay Fundamental Analyses, Veru (NASDAQ:VERU) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -64.41 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of VERU as of December 2024 is 0.52. This means that VERU is currently overvalued and has a potential downside of -20%.
Is VERU a buy, sell or hold?
Veru has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy VERU.
  • Strong Buy: 2
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for VERU stock price target?
According to ValueRays Forecast Model, VERU Veru will be worth about 0.6 in December 2025. The stock is currently trading at 0.65. This means that the stock has a potential downside of -12.31%.
Issuer Forecast Upside
Wallstreet Target Price 3.4 423.1%
Analysts Target Price 3.3 412.3%
ValueRay Target Price 0.6 -12.3%